transplantologiyaТрансплантологияTransplantologiya. The Russian Journal of Transplantation2074-05062542-0909IPO Association of Transplantologists10.23873/2074-0506-2018-10-1-42-49transplantologiya-215Research ArticleПРОБЛЕМНЫЕ АСПЕКТЫPROBLEMATIC ASPECTSОсновные принципы иммуносупрессивной терапии после трансплантации почкиThe basic principles of immunosuppressive therapy after kidney transplantationСусловД. Н.SuslovD. N.

канд. мед. наук, руководитель группы экспериментальной хирургии

Cand. Med. Sci., Head of the Experimental Surgery Group

susloff.dmit@yandex.ruФГБУ «Российский научный центр радиологии и хирургических технологий им. акад. А.М. Гранова» МЗ РФРоссияRussian Scientific Center of Radiology and Surgical Technologies n.a. acad. A.M. GranovRussian Federation2018280320181014249Copyright © Суслов Д.Н., 20182018Суслов Д.Н.Suslov D.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.jtransplantologiya.ru/jour/article/view/215

В статье рассмотрены медицинские и организационные вопросы индивидуализации иммуносупрессивной терапии у реципиентов почечных аллотрансплантатов. Основой нефропротективных схем терапии в последние годы становятся m-TOR-ингибиторы. Доступность этих препаратов для нуждающихся пациентов представляется недостаточно свободной. В то же время их более широкое применение в клинической трансплантологии не только повлечет за собой увеличение срока функционирования пересаженной почки, уменьшение рисков развития вирусных инфекций и онкологических заболеваний в отдаленном периоде после пересадки почки, но и позволит рационально использовать бюджетные средства для лечения подобных пациентов.

The article deals with medical and organizational issues of individually-adapted immunosuppressive therapy in renal allograft recipients. In the recent years, the basis of nephroprotective therapy schemes includes m-TOR inhibitors. The accessibility of these drugs for those in need is limited. Meanwhile, a more widespread use of these drugs in clinical transplantation would both increase the life span of a transplanted kidney, and reduce the risk of viral infections and cancer in the long-term after kidney transplantation, and would also allow a rational use of budget funds for the treatment of such patients.

иммуносупрессивная терапияиндивидуализациядоступностьm-TOR-ингибиторыimmunosuppressive therapyindividual adaptationaccessibilitym-TOR inhibitorsReferencesЛекарственный мониторинг и взаимозаменяемость оригинальных и генерических иммунодепрессантов с узким терапевтическим индексом. Национальные клинические рекомендации. М., 2014. 23 с.Drug monitoring and interchangeability of original and generic, immunodepressive drugs with narrow therapeutic index. National clinical guidelines. Mos-cow, 2014. 23 p.Kuypers D.R. Benefit-risk assessment of sirolimus in renal transplantation. Drug Saf. 2005;28(2):153–181. PMID:15691225Kuypers D.R. Benefit-risk assessment of sirolimus in renal transplantation. Drug Saf. 2005;28(2):153–181. PMID:15691225Halloran P.F. Immunosuppressive drugs for kidney transplantation. N. Engl. J. Med. 2004;351(26):2715–2729. PMID:15616206 https://doi.org/10.1056/ NEJMra033540Halloran P.F. Immunosuppressive drugs for kidney transplantation. N Engl J Med. 2004;351(26):2715–2729. PMID:15616206 DOI:10.1056/NEJM-ra033540Heemann U., Viklicky O. The role of belataceptin transplantation: results and implications of clinical trials in the context of other new biological immunosuppressant agents. Clin. Transplant. 2013;27(1):E3–11. PMID:23199344 DOI:10.1111/ctr.12044Heemann U., Viklicky O. The role of belataceptin transplantation: results and implications of clinical trials in the context of other new biological immunosuppressant agents. Clin Transplant. 2013;27(1):E3-11. PMID:23199344 DOI:10.1111/ctr.12044Opelz G., Dohler B. Influence of Immunosuppressive Regimens on Graft Survival and Secondary Outcomes after Kidney Transplantation. Transplantation. 2009;87(6):795–802. PMID:19300179 DOI:10.1097/TP.0b013e318199c1c7Opelz G., Dohler B. Influence of Immunosuppressive Regimens on Graft Survival and Secondary Outcomes after Kidney Transplantation. Transplantation. 2009;87(6):795–802. PMID:19300179 DOI:10.1097/TP.0b013e318199c1c7Morris P.J. Transplantation – a medical miracle of the 20th century. N. Engl. J. Med. 2004;351(26):2678– 2680. PMID:15616201 DOI:10.1056/ NEJMp048256Morris P.J. Transplantation – a medical miracle of the 20th century. N Engl J Med. 2004;351(26):2678–2680. PMID:15616201 DOI:10.1056/NEJMp048256Campbell S., McDonald S., Chang S. et al. Chapter 8. Transplantation. In: McDonald S., Chang S., Excell L., eds. ANZDATA registry report 2007. Adelaide, South Australia: Australia and New Zealand Dialysis and Transplant Registry, 2007.Campbell S., McDonald S., Chang S., et al. Chapter 8. Transplantation. In: McDonald S., Chang S., Excell L., eds. ANZDATA registry report 2007. Adelaide, South Australia: Australia and New Zealand Dialysis and Transplant Registry, 2007.Jain K.K. From molecular diagnostics to personalized medicine. The IBC Workshop, London, UK, 1st May, 2002. Exp. Rev. Mol. Diagn. 2002;2(4):299–301. DOI:10.1586/14737159.2.4.299Jain K.K. From molecular diagnostics to personalized medicine. The IBC Workshop, London, UK, 1st May, 2002. Exp Rev Mol Diagn. 2002;2(4):299–301. DOI:10.1586/14737159.2.4.299Об обращении лекарственных средств. Федеральный закон от 12.04.2010 № 61ФЗ. Ред. 25.11.2013. URL: https://normativ. kontur.ru/document?moduleId-=1&documentId=304074On the circulation of medicines. Federal Law of 12.04.2010, № 61FL. November 25, 2013 ed. Available at: https://normativ.kontur.ru/document?moduleI d=1&documentId=304074Даль В.И. Толковый словарь живого великорусского языка: в 4 т. М.: Русский язык, 1978–1980.Dal' V.I. Explanatory dictionary of the living Great Russian language: in 4 volumes. Moscow: Russkiy yazyk Publ., 1978-1980.Юргель Н.В., Тельнова Е.А. ДЛО – ОНЛС, «7 нозологий», а что дальше? Вестник Росздравнадзора. 2008;(5):4–Yurgel' N.V., Tel'nova E.A. ADS – PNM, "7 nosologies," and then what? Vestnik Roszdravnadzora. 2008;(5):4–21. Available at: http://www.remedium.ru/ public/journal/vr/2008/VR_05_2008.pdfURL: http://www.remedium.ru/ public/journal/vr/2008/VR_05_2008.pdfPascual J., Boletisb J.N., Campistolc J.M. Everolimus (Certican) in renal transplantation: a review of clinical trial data, current usage, and future directions. Transplant Rev. 2006;20(1):1–18. DOI:10.1016/j.trre.2005.10.005Pascual J., Boletisb J.N., Campistolc J.M. Everolimus (Certican) in renal transplantation: a review of clinical trial data, current usage, and future directions. Transplant. Rev. 2006;20(1):1–18. DOI:10.1016/j.trre.2005.10.005Ormiston J.A., Serruys P.W., Regar E., et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB) a prospective open-label trial. Lancet. 2008;371(9616):899–907. PMID:18342684 DOI:10.1016/S0140-6736(08)60415-8Ormiston J.A., Serruys P.W., Regar E. et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB) a prospective open-label trial. Lancet. 2008;371(9616):899–907. PMID:18342684 DOI:10.1016/S0140-6736(08)60415-8Ponticelli C. Can mTOR inhibitors reduce the risk of late kidney allograft failure? Transpl Int. 2008;21(1):2–10. PMID:17635837 DOI:10.1111/j.1432-2277.2007.00524.xPonticelli C. Can mTOR inhibitors reduce the risk of late kidney allograft failure? Transpl. Int. 2008;21(1):2–10. PMID:17635837 DOI:10.1111/j.1432-2277.2007.00524.xCruzado J.M. Nonimmunosuppressive effects of mammalian target of rapamycin inhibitors. Transplant Rev. (Orlan-do). 2008;22(1):73–81. PMID:18631860 DOI:10.1016/j.trre.2007.09.003Cruzado J.M. Nonimmunosuppressive effects of mammalian target of rapamycin inhibitors. Transplant. Rev. (Orlan-do). 2008;22(1):73–81. PMID:18631860 DOI:10.1016/j.trre.2007.09.003Contreras A.G., Dormond O., Edelbauer M., et al. mTOR-understanding the clinical effects. Transplant Proc. 2008;40(10 Suppl):S9–S12. PMID:19100913 DOI:10.1016/j.transproceed.2008.10.011Contreras A.G., Dormond O., Edelbauer M. et al. mTOR-understandin g the clinical effects. Transplant. Proc. 2008;40(10, Suppl.):S9–S12. PMID:19100913 DOI:10.1016/j.transproceed.2008.10.011Hudes G.R. Targeting mTOR in renal cell carcinoma. Cancer. 2009;115(10 Suppl):2313–2320. PMID:19402072 DOI:10.1002/cncr.24239Hudes G.R. Targeting mTOR in renal cell carcinoma. Cancer. 2009;115(10, Suppl.):2313–2320. PMID:19402072 DOI:10.1002/cncr.24239Eisen H. Long-term cardiovascular risk in transplantation--insights from the use of everolimus in heart transplantation. Nephrol Dial Transplant. 2006;21(Suppl 3):iii9–13. PMID:16815858 DOI:10.1093/ndt/gfl295Eisen H. Long-term cardiovascular risk in transplantation--insights from the use of everolimus in heart transplantation. Nephrol. Dial. Transplant. 2006;21(Suppl. 3):iii9–13. PMID:16815858 DOI:10.1093/ndt/gfl295Schuler W., Sedrani R., Cottens S., et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation. 1997;64(1):36–42. PMID:9233698Schuler W., Sedrani R., Cottens S. et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation. 1997;64(1):36–42. PMID:9233698Guba M., Pratschke J., Hugo C., et al. Early conversion to a sirolimus-based, calcineurin-inhibitor-free immunosuppression in the SMART trial: observational results at 24 and 36months after transplantation. Transplant Int. 2012;25(4):416–423. PMID:22320241 DOI:10.1111/j.1432-2277.2012.01432.xGuba M., Pratschke J., Hugo C. et al. Early conversion to a sirolimus-based, calcineurin-inhibitor-free immunosuppression in the SMART trial: observational results at 24 and 36months after transplantation. Transplant. Int. 2012;25(4):416–423. PMID:22320241 DOI:10.1111/j.1432-2277.2012.01432.xGuba M., Pratschke J., Hugo C, et al. Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial. Transplantation. 2010;90(2):175– 183. PMID:20463641 DOI:10.1097/ TP.0b013e3181e11798Guba M., Pratschke J., Hugo C. et al. Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial. Transplantation. 2010;90(2):175– 183. PMID:20463641 DOI:10.1097/ TP.0b013e3181e11798Jun H., Kim M.G., Jung C.W. Clinical advantages including medication adheren ce with conversion to once-daily advagraf and sirolimus combination in stable kidney recipients. Int J Clin Pharmacol Ther. 2016;54(2):81–86. PMID:26709601 DOI:10.5414/CP202518.Jun H., Kim M.G., Jung C.W. Clinical advantages including medication adhe rence with conversion to once-daily advagraf and sirolimus combination in stable kidney recipients. Int. J. Clin. Pharmacol. Ther. 2016;54(2):81–86. PMID:26709601 DOI:10.5414/CP202518.Hariharan S., McBride M.A., Cherikh W.S., et al. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int. 2002;62(1):311–318. PMID:12081593 DOI:10.1046/j.1523-1755.2002.00424.xHariharan S., McBride M.A., Cherikh W.S. et al. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int. 2002;62(1):311–318. PMID:12081593 DOI:10.1046/j.1523-1755.2002.00424.xHariharan S., McBride M.A., Cherikh W.S. et al. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int. 2002;62(1):311–318. PMID:12081593 DOI:10.1046/j.1523-1755.2002.00424.x

The authors declare that there are no conflicts of interest present.